Charles River ($CRL) presenting at J.P.

Filed with the SEC on January 13, 2026 · Summarized by InvestorsBot

Charles River ($CRL) presenting at J.P. Morgan 44th Annual Healthcare Conf on Jan 13, 2026 ~1:30 PM ET — management to review strategy, business developments & trends. Slide deck posted on the IR site. 🧪📈 #Healthcare #Biotech #Investing

Prelim: Charles River ($CRL) says DSA demand improved through H2 2025, with preliminary Q4'25 DSA net book‑to‑bill ≈1.1x. Company warns these are estimates and may change with audited results. ⚠️🔁 #Biotech #DrugDev

Investors: Charles River ($CRL) is continuing its review of 2025 results; actual 2025 financials may differ materially from the preliminary figures disclosed at the JP Morgan presentation. See slide presentation on IR site. 🔎 #Investing #Healthcare

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Feb 25, 2026: $CRL agreed to sell its CDMO and Cell Solutions businesses to GI Partners for primarily…

8-K · February 25, 2026

Charles River ($CRL) filed an 8-K (Item 9.01) on Feb 18, 2026 — Exhibits: 99.1 press release (dated Feb…

8-K · February 18, 2026

Charles River ($CRL) 8‑K (Feb 18, 2026): issued press release with Q4 and FY results for period ended Dec…

8-K · February 18, 2026

Charles River ($CRL) filed an 8‑K (Item 9.01) disclosing an Employment Offer Letter with Glenn Coleman…

8-K · February 18, 2026

Charles River names Glenn Coleman Corporate Executive VP & CFO, tentative start April 6, 2026.

8-K · February 18, 2026

Charles River ($CRL): Q4 DSA net book-to-bill ~1.1x as demand improved through H2 2025, led by small/mid…

8-K · January 13, 2026